Articles Tagged With:
-
L-methylfolate for Bipolar Disorder
L-methylfolate improves some symptoms in major depression in people with type 1 bipolar.
-
Rehabilitation From Neurological Insults: The Role of Music-based Interventions
The authors of this comprehensive review article found evidence for the use of music-based interventions as part of rehabilitation across a broad range of neurological disorders.
-
Ethics and Science, Cannabinoids and Healthcare
Perhaps no topic is more controversial than the use of marijuana in clinical practice. Within the United States, there are an estimated 55 million recent active users, defined as one to two uses within the previous year, and 35 million regular users, defined as one to two uses per month.
-
Thrombectomy Is Effective Up to 24 Hours After Stroke – the DAWN Trial
-
Isolated Amyloid Myopathy
Isolated amyloid myopathy is a rare disorder that can be distinguished from systemic amyloidosis with myopathy by clinical, biochemical, and muscle biopsy histologic criteria.
-
Advanced Cardiac Life Support Updates
The American Heart Association Advanced Cardiac Life Support guidelines are recognized as the authoritative reference for acute cardiopulmonary resuscitation. Emergency medicine providers should be thoroughly familiar with these guidelines.
-
TBI in Prodromal Parkinson’s Disease
This population-based study using Medicare data demonstrated that in the five years prior to diagnosis of Parkinson’s disease (PD), when compared with age-matched controls, those who were diagnosed with PD had a higher incidence of traumatic brain injury (TBI). The TBI was rated as mild and concussive and was most often related to falls.
-
Blockade of CGRP for Migraine Prevention: Promising, but Not a Cure
Blockade of calcitonin gene-related peptide in patients with chronic or episodic migraine results in the prevention of about two headache days a month compared to placebo.
-
The Incidence of Dementia May Be Declining
In community-dwelling people from Bronx County, New York, there was a sharp decrease in dementia incidence in those born after mid-1929, which could not be readily explained by changes in the prevalence of cardiovascular diseases, higher education, or increased racial/ethnic diversity.
-
How Helpful Is Bevacizumab in Recurrent Glioblastoma?
In a randomized Phase III trial, the addition of bevacizumab to lomustine did not improve overall survival in patients with recurrent glioblastoma compared to lomustine alone.